Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Xisimin (Loratadine) vs Clarityne in Healthy Subjects
NCT03196531Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Xisimin in allergic rhinitis (AR) and urticaria (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at 96 hours, Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Time at 96 hours and 1 more. Started Nov 2017; status: completed.
02
Drugs
Xisimin
03
Conditions
allergic rhinitis (AR)urticaria
Beyond the preview
Go deeper on NCT03196531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196531.